Related Experiment Video
Updated: Apr 21, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
1.6K
Advances in malignant peritoneal mesothelioma
Shoubo Cao1, Shi Jin, Jingyan Cao
1Department of Medical Oncology, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, 150081, China, cs.bo@163.com.
International Journal of Colorectal Disease
|October 22, 2014
Summary
Malignant peritoneal mesothelioma (MPM) is a rare cancer. Advances in treatment, particularly cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), significantly improve survival rates for selected patients.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Imaging
Background:
- Malignant mesothelioma is a rare, aggressive cancer affecting mesothelial surfaces.
- Peritoneal mesothelioma accounts for 20% of all mesothelioma cases.
- Increasing incidence, high misdiagnosis rates, and poor prognosis characterize this disease.
Purpose of the Study:
- To review recent advances in the epidemiology, diagnosis, and management of malignant peritoneal mesothelioma (MPM).
- To highlight key findings in clinical presentations, radiological features, and prognostic factors.
- To evaluate the efficacy of current treatment strategies for MPM.
Main Methods:
- Literature review focusing on epidemiological, clinical, radiological, diagnostic, and management aspects of MPM.
- Analysis of diagnostic modalities including CT, MRI, and PET scans.
- Evaluation of treatment outcomes for various therapeutic approaches.
Main Results:
- Asbestos, SV40, and radiation are linked to MPM pathogenesis.
- Abdominal distension and pain are common symptoms; immunohistochemistry confirms diagnosis.
- Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) shows promising survival rates (29.5-92 months median survival, 39-63% 5-year survival).
Conclusions:
- CRS and HIPEC are the standard treatment for eligible MPM patients.
- Multimodality treatment including chemotherapy, radiotherapy, and immunotherapy benefits unresectable cases.
- Advances in management offer improved outcomes for malignant peritoneal mesothelioma.
